Breaking News

AlzeCure Selects Promising Drug Candidate ACD137

Starts the preclinical development phase with the goal of developing a new pain-relieving drug.

Author Image

By: Charlie Sternberg

Associate Editor

AlzeCure Pharma AB, a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, has selected a TrkA-NAM drug candidate, ACD137, and started the preclinical development phase with the compound.   “AlzeCure’s unique TrkA-NAM substances have extremely selective effects so that optimal pain-relieving effect is achievable without inducing side effects. As the TrkA-NAM substances are small molecules, they c...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters